Slide 1: Dimerix Bioshares Presentation July 2023
y al use onl For person ACTIONS FSGS CLINICAL STUDY @ Dimerix (ASX:DXB) Bioshares Presentation July 2023 Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be ma
Slide 3: Conference theme: partnering and raising capital
Conference theme: partnering and raising capital Questions posed to Dimerix: 1. How is the company’s program in FSGS progressing and what are the timelines? 2. What are the trends in licensing drug development? 3. What type of partnering deals are occurring in the kidney disease space? & How might D
Slide 4: Dimerix - in context
DIMERIX - IN CONTEXT ACTIGNS FSGS CLINICAL STUDY For personal use only @ Dimerix
Slide 5: Dimerix in context
Dimerix in context 2 Cc je) oO 12) =) © Cc Oo @°% 6 w@ e@ B Advanced partnering Near term Phase 3 interim negotiations with offers analysis results received from multiple Oo announced (Q124) parties for various LL e territories! ee Head candidate: Va ma DMX-200 rocal segmental _Avomeriipselerosis Or
Slide 6: For personal use only
For personal use only • • • • • • • • •
Slide 7: What is Focal Segmental Glomerulosclerosis (FSGS)?
What is Focal Segmental Glomerulosclerosis (FSGS)? a Normal glomerulus: * On average FSGS progresses to kidney failure within 5 years after onset of proteinuria’ ¢ Affects adults and children * Caused by a variety of conditions - primary FSGS, genetic FSGS, FSGS of unknown cause and secondary FSGS?
Slide 8: Competitive landscape in FSGS
Competitive landscape in FSGS Phase 1 Phase 2 Phase 3 Company © B764198 je) a ee ro) Atrasentan Chinook a s VAR-200 Zyversa VB119 Valenza Bio DMX-200 is the only therapy in phase 3 development @ Dimerix
Slide 9: ACTION3 Phase 3 clinical trial
O ACTI IN3 Phase 3 clinical trial FSGS CLINICAL STUDY randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Part 1: Part 2: Part 3: oe 72 patients @ 35 weeks treatment 144 patients @ 35 weeks treatment All patients @ 104
Slide 10: For personal use only
For personal use only • • • • • • • • •
Slide 11: What are the trends in licensing drug development?
ACTIGNS FSGS CLINICAL STUDY WHAT ARE THE TRENDS IN LICENSING DRUG DEVELOPMENT? For personal use only @ Dimerix
Slide 12: Global partnering trends — Q1 2023
Global partnering trends — Q1 2023 * Some picking up bargain assets, but large majority Big Pharma Pays Well for Phase II as POC Returns” : . . . Median Upfront Cash & Equity by Stage at Signing by Big Pharma ~ 2018-2022 ($M) “business as usual” licensing deals se 323 Cc Biopharma R&D licensing part
Slide 13: What type of partnering deals are occurring in the kidney disease space?
oe ACTIGNS FSGS CLINICAL STUDY WHAT TYPE OF PARTNERING DEALS ARE OCCURRING IN THE KIDNEY DISEASE SPACE? For personal use only ol @ Dimerix
Slide 14: For personal use only
1600 AstraZeneca + Cincor (Global) For personal use only Ph2, $522M upfront 1400 • • 1200 Travere + CSL Vifor (EU, UK) Ph3, $55M upfront Roche + Ionis (Global) Ph3, $55M upfront 1000 Novo Nordisk + Ventus (Global) Deal size (US$M) Cyclerion + Akebia (Global) Ph1, $70M upfront Ph2, $3M upfront 800 Ka
Slide 15: How might Dimerix look to structure a deal, and what level of data will be required?
ACTIGNS FSGS CLINICAL STUDY HOW MIGHT DIMERIX LOOK TO STRUCTURE A DEAL, AND WHAT LEVEL OF DATA WILL BE REQUIRED? For personal use only @ Dimerix al
Slide 16: For personal use only
For personal use only • • • • • • • • • • • •
Slide 17: Dimerix partner
Dimerix partner The ideal partner: = Regulatory expertise in proposed territory O ay Sales/marketing infrastructure in place to support indication For personal us Due diligence ° Akey part of the negotiation process * Stakeholder identification & management * Key decision maker engagement * Benefits
Slide 18: Late stage, phase clinical development asset
Late stage, phase 3 clinical development asset 2 Cc je) oO Yn =) © Cc Oo @°% 6 2 @ e Orphan D. Esti d >$3b global & cmmoneceaime, _Advanced partnering providing pretection ‘market size p2°— Near term hase 3 interim got . through data exclusivity? 203,0003 patients across _ analysis results received
Slide 19: Well positioned to deliver against strategic plan
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 42